Pure Global
NCT06315686

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

A Single-center Prospective Cohort Study to Explore the Efficacy and Prognosis of Dynamic Monitoring of Cerebrospinal Fluid ctDNA
Jiangsu Province Nanjing Brain Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
pemetrexed
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu Province Nanjing Brain Hospital
Location
Suzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Sep 29, 2022
End date
Dec 31, 2024
Enrollment
20 participants
Primary outcome

The progression-free survival time（PFS）

Summary

Focusing on advanced EGFR mutation in NSCLC patients with leptomeningeal metastasis,
 vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was used to
 dynamically monitor ctDNA in cerebrospinal fluid (CSF), analyze the ctDNA gene mutation
 profile of CSF in different patients, and explore the relationship between ctDNA and efficacy
 and prognosis.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06315686
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06315686 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.